Arcellx (ACLX) Non Operating Income (2021 - 2025)
Arcellx's quarterly Non Operating Income came in at $5.6 million in Q4 2025, down 25.94% year-on-year from $7.6 million in Q4 2024, and down 6.41% quarter-over-quarter from $6.0 million in Q3 2025.
Arcellx has reported Non Operating Income for 5 years, with the latest figure at $5.6 million in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income fell 25.94% year-over-year to $5.6 million; the trailing twelve-month figure through Dec 2025 stood at $24.2 million (down 25.0% YoY), and the FY2025 full-year result was $24.2 million, down 25.0% from the prior year.
- Non Operating Income for Q4 2025 stood at $5.6 million, down from $6.0 million in the prior quarter.
- The five-year high for Non Operating Income was $8.6 million in Q1 2024, with the low at $1000.0 in Q1 2021.
- Average Non Operating Income over 5 years is $3.9 million, with a median of $5.4 million recorded in 2023.
- Year-over-year, Non Operating Income jumped 51700.0% in 2022 and declined 26.41% in 2025.
- Tracing ACLX's Non Operating Income over 5 years: stood at $28000.0 in 2021, then jumped by 3514.29% to $1.0 million in 2022, then soared by 440.22% to $5.5 million in 2023, then soared by 38.58% to $7.6 million in 2024, then dropped by 25.94% to $5.6 million in 2025.
- The last three Non Operating Income figures came in at $5.6 million (Q4 2025), $6.0 million (Q3 2025), and $6.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 5.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.61 Mn |
| Sep 30, 2025 | 6.00 Mn |
| Jun 30, 2025 | 5.98 Mn |
| Mar 31, 2025 | 6.63 Mn |
| Dec 31, 2024 | 7.58 Mn |
| Sep 30, 2024 | 7.97 Mn |
| Jun 30, 2024 | 8.13 Mn |
| Mar 31, 2024 | 8.61 Mn |
| Dec 31, 2023 | 5.47 Mn |
| Sep 30, 2023 | 5.52 Mn |
| Jun 30, 2023 | 5.42 Mn |
| Mar 31, 2023 | 3.44 Mn |
| Dec 31, 2022 | 1.01 Mn |
| Sep 30, 2022 | 1.00 Mn |
| Jun 30, 2022 | 518,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | 28,000.00 |
| Sep 30, 2021 | 19,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 1,000.00 |